Related Experiment Video

Updated: Jan 6, 2026

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
07:14

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

Published on: May 23, 2025

1.5K

Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET

Annie Lemelin1, Delphine Maucort-Boulch2,3, Elisabeth Castel-Kremer4

  • 1Service de Gastroentérologie et d'Oncologie Médicale, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.

Neuroendocrinology
|October 7, 2019
PubMed
Abstract

Insights

Elderly patients with metastatic neuroendocrine tumors (mNET) experience poorer survival and receive less treatment. This study highlights undertreatment and worse outcomes in older mNET patients compared to younger individuals.

Area of Science:

  • Oncology
  • Geriatric Medicine
  • Cancer Research

Background:

  • Neuroendocrine tumor (NET) incidence is increasing, particularly in the elderly.
  • Limited data exists on the characteristics, treatment, and outcomes of elderly metastatic NET (mNET) patients.

Purpose of the Study:

  • To compare the characteristics, treatment patterns, and outcomes of elderly (≥70 years) versus younger (<70 years) metastatic NET patients.
  • To identify factors influencing survival in elderly mNET patients.

Main Methods:

  • Analysis of the Lyon Real-life Evidence in Metastatic NeuroEndocrine Tumors (LyREMeNET) study cohort.
  • Inclusion of consecutive mNET patients diagnosed between 1990 and 2017.
  • Comparison of elderly patients (≥70 years) with younger patients (<70 years).

Main Results:

  • Elderly patients (23%) had synchronous metastasis more frequently.
  • Elderly patients received significantly fewer treatment lines and less chemotherapy, targeted therapy, peptide receptor radionuclide therapy, and locoregional interventions.
  • Median overall survival was significantly shorter in elderly patients (5.2 vs. 9.6 years), with disease progression as the most frequent cause of death.

Conclusions:

  • Elderly patients (≥70 years) with mNET exhibit poorer survival outcomes.
  • Older mNET patients are significantly undertreated compared to their younger counterparts.
  • Age is an independent negative prognostic factor for overall survival in mNET patients.
Keywords:
ElderlyMetastatic neuroendocrine tumorNeuroendocrine tumorPrognosisTreatment

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.8K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176